Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17307557 | 0.93 | BRD4 (0.41) | BRD4CHRNB2CHRNA4MEN1APAF1 | |
| SCHEMBL1028127 | 0.85 | BRD4 (0.44) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL1026164 | 0.81 | BRD4 (0.47) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL12547903 | 0.78 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL6850467 | 0.78 | BRD4 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL722050 | 0.77 | BRD4 (0.46) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL6850450 | 0.74 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL30619654 | 0.74 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL20512889 | 0.74 | BRD4 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL29133012 | 0.74 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEXA THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6D, PDE6A | BRD4 2579/4885CHRNB2 3144/4885CHRNA4 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.